A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
← catalyst calendarNCT06200207 · readout in 43 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
680estimated
Sites
217
Countries
Argentina, Australia, Bulgaria +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-01 | actual | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-08 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Heart Failure
- Systemic Inflammation
Interventions
- Drug: Ziltivekimab
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)
measured From randomisation (month 0) to end-of-treatment (month 12)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed